Division of Harvard Bioscience Inc.
Latest From Biochrom Ltd.
Q4 device financing reached $902 million versus Q3’s $734 million, while device M&A dollar volume increased $19 billion, from Q3’s $4.9 billion. Diagnostics companies raised $750 million, an 85% rise over the previous quarter’s $405 million; although diagnostics M&A totaled just $1 billion, it was the most deal-active quarter of 2014 with 11 transactions.
BMS teamed up with F-start Alpha and also received an option to acquire; BD bought hospital care systems provider CareFusion for $11.8 billion. IPOs made up nearly a quarter of total dollars in both biopharma and device financing.
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Pharmacia Biotech Ltd.
- Western Europe
- Parent & Subsidiaries
- Harvard Bioscience Inc.
- Senior Management
- David Parr, Managing Dir.
- Contact Info
Phone: (44) 1223 423723
22 Cambridge Science Pk.
Cambridge, CB4 0FJ
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.